LQDA Liquidia Technologies Inc
Company Analysis
Latest News
๐ด Liquidia Technologies is trading 4.3% down as immediate catalyst remains unclear
Liquidia Technologies is trading at $70.53, down 4.27%, with no clear immediate catalyst identified. - No company-specific announcement explaining the...
๐ข Liquidia Technologies is trading 4.1% up โ immediate catalyst unclear
Liquidia Technologies is trading 4.12% up at $71.25 on September 28, 2026, with the immediate catalyst unclear. - No confirmed company-specific announcement...
๐ข Liquidia Technologies is trading 4.8% up in pre-market with no confirmed company-specific catalyst
Liquidia Technologies is trading 4.8% higher at $71.71 in pre-market on September 28, with no new company-specific announcement explaining the gain surfaced in...
๐ด Liquidia Technologies is trading 4.05% down today after Zacks Research downgrade over Yutrepia competition
Liquidia Technologies is trading 4.05% down at $68.08 after Zacks Research downgraded it from hold to strong sell on September 24, 2026, citing intensifying...
Liquidia Technologies Downgraded to Strong Sell Amid Yutrepia Competition
Zacks Research downgraded Liquidia Technologies (NASDAQ: LQDA) from hold to strong sell on September 24, 2026. The rating action follows concerns regarding...
๐ข Liquidia Technologies is trading 4.39% up today with catalyst unclear
Liquidia Technologies is trading 4.39% higher at $70.45, with no clear company-specific catalyst identified. - No clear company-specific announcement dated...
Liquidia Technologies Upgraded to Buy, Following 1,842% Revenue Surge
Wall Street Zen upgraded Liquidia Technologies (NASDAQ: LQDA) from Hold to Buy. The broader analyst consensus remains at Hold with an average price target of...
๐ข Liquidia Technologies is trading 4.1% up today with no new company-specific announcement identified
Liquidia Technologies is trading at $68.42, up 4.10%, with no new company-specific announcement dated September 16, 2026 identified. - Latest listed releases:...
Liquidia's YUTREPIA Granted FDA Fast Track Designation for Raynaud's Phenomenon
Liquidia Corporation announced that its product, YUTREPIAยฎ (treprostinil) inhalation powder, has received Fast Track Designation from the U.S. Food and Drug...
๐ข Liquidia Technologies is trading 4.31% up today on broad biotech strength
Liquidia Technologies is trading 4.31% up at $69.80 on broad strength across biotechnology stocks. - Biotech is up 2.75% on patent-related enthusiasm and...
๐ด Liquidia Technologies is trading 4.2% down in pre-market today as Nasdaq Composite falls 0.91%
Liquidia Technologies is trading 4.2% down now at $65.31 after broader markets weakened ahead of U.S. economic data and amid elevated geopolitical and...
Farallon Capital Management Initiates $327M Stake in Liquidia Corp
In a quarterly disclosure filed on August 14, 2026, major investment firm Farallon Capital Management revealed a new significant position in Liquidia...
๐ด Liquidia Technologies is trading 4.1% down today amid biotech pullback after recent rally
Liquidia Technologies is trading 4.1% down at $72.23, with the decline appearing tied mainly to a broader biotech pullback after the sectorโs recent rally,...
๐ด Liquidia Technologies is trading 4.76% down today as Nasdaq falls 1.36%
Liquidia Technologies is trading 4.76% down at $73.89 as U.S. markets weaken, with the Nasdaq Composite down 1.36% and the S&P 500 down 0.58%. - No fresh...
๐ข Liquidia Technologies is trading 4.1% up today after Raymond James raised price target to $106
Liquidia Technologies is trading 4.08% up now at $77.48 after Raymond James raised its price target to $106 from $68 while maintaining a Strong Buy rating. -...
๐ข Liquidia Technologies is trading 4.5% up today, rebounding after a sharp two-session decline
Liquidia Technologies is trading 4.5% up at $75.36, reversing part of its sharp two-session decline without a clearly reported catalyst. - Latest coverage...
๐ด Liquidia Technologies is trading 4.8% down today after adjusted EPS missed estimates
Liquidia Technologies is trading 4.8% down now at $75.04 after adjusted EPS of $0.74 missed the $0.76 consensus following its August 12, 2026 earnings...
Liquidia's Blockbuster Drug Keeps Selling, So Why Are Investors Punishing the Stock Over Two Pennies?
Shares of Liquidia plunged 10.4% to $78.94 on Tuesday after the biotech's second-quarter earnings fell a hair short of Wall Street targets, exposing investor...
๐ด Liquidia Technologies is trading 10.35% down today after second-quarter adjusted EPS missed consensus
Liquidia Technologies is trading 10.35% down now at $78.94 after second-quarter adjusted EPS of $0.74 missed the $0.76 consensus. - Revenue reached $171.68...
๐ด Liquidia Technologies is trading 5% down today after adjusted EPS missed expectations
Liquidia Technologies is trading 5.17% down at $83.49 after adjusted EPS missed expectations despite revenue slightly exceeding forecasts. - Adjusted EPS was...